摘要
目的 探讨乳腺癌中CD9的表达及临床病理意义。方法 应用免疫组化S -P法 ,检测 10 6例乳腺癌中CD9的表达。结果 39.6 % (4 2 10 6 )乳腺癌CD9呈阳性表达 ;31.1% (33 10 6 )病例呈不同程度表达降低 ;2 9.3% (31 10 6 )病例CD9表达阴性。CD9表达与组织学分型无关 (P >0 .0 5 ) ,与组织学分级和临床分期呈显著相关 (分别P <0 .0 5 ,P <0 .0 1)。对 6 2例随访病例统计发现 ,存活组病人CD9表达率和强度略高于死亡组 ,但差别无统计学意义 (P >0 .0 5 ) ;术后接受过系统化疗或内分泌治疗的病例中 ,CD9阳性病人的 5年生存率显著高于阴性或表达下降病人 (P <0 .0 5 )。结论 CD9表达与乳腺癌组织学分级和临床分期相关 ,阴性表达或表达降低的病人预后差 ,可作为术后病人进行化疗的重要参考指标。
Objective To investigate the expression of motility-related protein-1(MRP-1,CD9in breast carcinomas and the relaˉtionship between it's expression and the histopathological characteristics and prognosis of breast carcinomas.Methods Immunohistochemical method(S-P)was used to examine the expression of CD9proteins in paraffin-embedded specimens of106cases of breast carcinomas.Results Expression of CD9in106cases of breast carcinomas were different.29.2%(31.106)were positive,31.1%(33.106)were weak positive,and29.3%(31.106)were negative.Loss.reduc of CD9expression was closely correlated with histologic grades and clinic stages of breast carcinoˉma,but not with5-year revival rates(P<0.05,P<0.01respectively).In patients who received regular chemotherapy,the5-year revivˉal rates of the positive expression of CD9was higher than the negative expression of CD9(P<0.05).Conclusions Loss.reduce of CD9exˉpression is not an independent prognostic factor for predicting progression of breast carcinomas,but can be as an indictor of chemotherapy to the post-operation patiens.
出处
《宁夏医学杂志》
CAS
2004年第7期393-395,共3页
Ningxia Medical Journal
